The fatty acid receptor FFA1/GPR40 a decade later: How much do we know?

Trends in Endocrinology and Metabolism

Volumn 24, Issue 8, 2013, Pages 398-407

  Mancini, Arturo D ^a   Poitout, Vincent ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Biased agonism; GPR40 FFA1; Insulin secretion; Pancreatic cell; Type 2 diabetes

Indexed keywords

FATTY ACID; G PROTEIN COUPLED RECEPTOR 40; GLUCOSE; INSULIN;

GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RELEASE; LIPOTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

EID: 84880964021     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2013.03.003     Document Type: Review

References (83)

1. Crespin S.R., et al. Stimulation of insulin secretion by infusion of free fatty acids. J. Clin. Invest. 1969, 48:1934-1943.
2. Stein D.T., et al. Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. J. Clin. Invest. 1996, 97:2728-2735.
3. Dobbins R., et al. A fatty acid-dependent step is critically important for both glucose- and non-glucose-stimulated insulin secretion. J. Clin. Invest. 1998, 101:2370-2376.
4. Gravena C., et al. Acute effects of fatty acids on insulin secretion from rat and human islets of Langerhans. J. Endocrinol. 2002, 173:73-80.
5. Nolan C.J., et al. Fatty acid signaling in the β-cell and insulin secretion. Diabetes 2006, 55(Suppl. 2):S16-S23.
6. Briscoe C.P., et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J. Biol. Chem. 2003, 278:11303-11311.
7. Itoh Y., et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 2003, 422:173-176.
8. Kotarsky K., et al. A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem. Biophys. Res. Commun. 2003, 301:406-410.
9. Nilsson N.E., et al. Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem. Biophys. Res. Commun. 2003, 303:1047-1052.
10. Le Poul E., et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J. Biol. Chem. 2003, 278:25481-25489.
11. Hirasawa A., et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat. Med. 2005, 11:90-94.
12. Burant C.F., et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2012, 379:1403-1411.
13. Kaku K., et al. Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care 2013, 36:245-250.
14. Leifke E., et al. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Clin. Pharmacol. Ther. 2012, 92:29-39.
15. Shapiro H., et al. Role of GPR40 in fatty acid action on the beta cell line INS-1E. Biochem. Biophys. Res. Commun. 2005, 335:97-104.
16. Itoh Y., Hinuma S. GPR40, a free fatty acid receptor on pancreatic beta cells, regulates insulin secretion. Hepatol. Res. 2005, 33:171-173.
17. Schnell S., et al. Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from beta-cells through activation of GPR40. Mol. Cell. Endocrinol. 2007, 263:173-180.
18. Salehi A., et al. Free fatty acid receptor 1 (FFA(1)R/GPR40) and its involvement in fatty-acid-stimulated insulin secretion. Cell Tissue Res. 2005, 322:207-215.
19. Briscoe C.P., et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br. J. Pharmacol. 2006, 148:619-628.
20. Steneberg P., et al. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab. 2005, 1:245-258.
21. Latour M.G., et al. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 2007, 56:1087-1094.
22. Lan H., et al. Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. Diabetes 2008, 57:2999-3006.
23. Kebede M., et al. The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 2008, 57:2432-2437.
24. Vettor R., et al. Loss-of-function mutation of the GPR40 gene associates with abnormal stimulated insulin secretion by acting on intracellular calcium mobilization. J. Clin. Endocrinol. Metab. 2008, 93:3541-3550.
25. Nagasumi K., et al. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 2009, 58:1067-1076.
26. Poitout V., et al. Glucolipotoxicity of the pancreatic beta cell. Biochim. Biophys. Acta 2010, 1801:289-298.
27. Alquier T., et al. Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. Diabetes 2009, 58:2607-2615.
28. Tan C.P., et al. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 2008, 57:2211-2219.
29. Doshi L.S., et al. Acute administration of GPR40 receptor agonist potentiates glucose-stimulated insulin secretion in vivo in the rat. Metabolism 2009, 58:333-343.
30. Pang Z., et al. GPR40 is partially required for insulin secretion following activation of beta3-adrenergic receptors. Mol. Cell. Endocrinol. 2010, 325:18-25.
31. Lin D.C., et al. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS ONE 2011, 6:e27270.
32. Luo J., et al. A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PLoS ONE 2012, 7:e46300.
33. Tsujihata Y., et al. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J. Pharmacol. Exp. Ther. 2011, 339:228-237.
34. Alquier T., Poitout V. GPR40: good cop, bad cop?. Diabetes 2009, 58:1035-1036.
35. Fontes G., et al. Glucolipotoxicity age-dependently impairs beta cell function in rats despite a marked increase in beta cell mass. Diabetologia 2010, 53:2369-2379.
36. Del Guerra S., et al. G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: the role of type 2 diabetes and fatty acids. Nutr. Metab. Cardiovasc. Dis. 2010, 20:22-25.
37. Bartoov-Shifman R., et al. Regulation of the gene encoding GPR40, a fatty acid receptor expressed selectively in pancreatic beta cells. J. Biol. Chem. 2007, 282:23561-23571.
38. Kebede M., et al. Glucose activates free fatty acid receptor 1 gene transcription via phosphatidylinositol-3-kinase-dependent O-GlcNAcylation of pancreas-duodenum homeobox-1. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:2376-2381.
39. Hagman D.K., et al. Palmitate inhibits insulin gene expression by altering PDX-1 nuclear localization and reducing MafA expression in isolated rat islets of Langerhans. J. Biol. Chem. 2005, 280:32413-32418.
40. Hagman D.K., et al. Cyclical and alternating infusions of glucose and intralipid in rats inhibit insulin gene expression and Pdx-1 binding in islets. Diabetes 2008, 57:424-431.
41. Sassmann A., et al. The Gq/G11-mediated signaling pathway is critical for autocrine potentiation of insulin secretion in mice. J. Clin. Invest. 2010, 120:2184-2193.
42. Seino S., et al. Dynamics of insulin secretion and the clinical implications for obesity and diabetes. J. Clin. Invest. 2011, 121:2118-2125.
43. Wang Z., Thurmond D.C. Mechanisms of biphasic insulin-granule exocytosis - roles of the cytoskeleton, small GTPases and SNARE proteins. J. Cell Sci. 2009, 122:893-903.
44. Ferdaoussi M., et al. G protein-coupled receptor (GPR)40-dependent potentiation of insulin secretion in mouse islets is mediated by protein kinase D1. Diabetologia 2012, 55:2682-2692.
45. 35S]thio)triphosphate binding studies reflects binding of an endogenous agonist. Mol. Pharmacol. 2007, 71:994-1005.
46. Gilon P., Henquin J.C. Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function. Endocr. Rev. 2001, 22:565-604.
47. 2+ channel and link to insulin release. Am. J. Physiol. Endocrinol. Metab. 2005, 289:E670-E677.
48. Ullrich S., et al. Effects of small FFA1 receptor agonists on insulin secreting cells. Diabetes 2011, 60(Suppl. 1):2023P.
49. Zhao Y.F., et al. Activation of ATP-sensitive potassium channels in rat pancreatic beta-cells by linoleic acid through both intracellular metabolites and membrane receptor signalling pathway. J. Endocrinol. 2008, 198:533-540.
50. + currents in primary cultured rat pancreatic beta-cells by linoleic acids. Endocrinology 2006, 147:674-682.
51. Kong K.C., et al. M3-muscarinic receptor promotes insulin release via receptor phosphorylation/arrestin-dependent activation of protein kinase D1. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:21181-21186.
52. Whalen E.J., et al. Therapeutic potential of beta-arrestin- and G protein-biased agonists. Trends Mol. Med. 2011, 17:126-139.
53. Schroder R., et al. Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells. Nat. Protoc. 2011, 6:1748-1760.
54. Oh da Y., et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010, 142:687-698.
55. Parker H.E., et al. Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 2009, 52:289-298.
56. Liou A.P., et al. The G protein-coupled receptor GPR40 directly mediates long chain fatty acid-induced secretion of cholecystokinin. Gastroenterology 2011, 140:903-912.
57. Edfalk S., et al. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 2008, 57:2280-2287.
58. Flodgren E., et al. GPR40 is expressed in glucagon producing cells and affects glucagon secretion. Biochem. Biophys. Res. Commun. 2007, 354:240-245.
59. 2+]i increase in pancreatic islet α-cells. J. Endocrinol. 2011, 210:173-179.
60. Hirasawa A., et al. Production and characterization of a monoclonal antibody against GPR40 (FFAR1; free fatty acid receptor 1). Biochem. Biophys. Res. Commun. 2008, 365:22-28.
61. Yashiro H., et al. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets. J. Pharmacol. Exp. Ther. 2012, 340:483-489.
62. Ma D., et al. Expression of free fatty acid receptor GPR40 in the neurogenic niche of adult monkey hippocampus. Hippocampus 2008, 18:326-333.
63. Ma D., et al. Expression of free fatty acid receptor GPR40 in the central nervous system of adult monkeys. Neurosci. Res. 2007, 58:394-401.
64. Nakamoto K., et al. Involvement of the long-chain fatty acid receptor GPR40 as a novel pain regulatory system. Brain Res. 2012, 1432:74-83.
65. Cartoni C., et al. Taste preference for fatty acids is mediated by GPR40 and GPR120. J. Neurosci. 2010, 30:8376-8382.
66. Hardy S., et al. Oleate promotes the proliferation of breast cancer cells via the G protein-coupled receptor GPR40. J. Biol. Chem. 2005, 280:13285-13291.
67. Honoré J.C., et al. Fatty acid receptor GPR40 mediates neuromicrovascular degeneration induced by transarachidonic acid in rodents. Arterioscler. Thromb. Vasc. Biol. 2013, 33:954-961.
68. Cornish J., et al. Modulation of osteoclastogenesis by fatty acids. Endocrinology 2008, 149:5688-5695.
69. Mieczkowska A., et al. Thiazolidinediones induced osteocyte apoptosis by a GPR40-dependent mechanism. J. Biol. Chem. 2012, 287:23517-23526.
70. Wauquier F., et al. the free fatty acid receptor G protein-coupled receptor 40 (GPR40) protects from bone loss through inhibition of osteoclast differentiation. J. Biol. Chem. 2013, 288:6542-6551.
71. Bharate S.B., et al. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes. Expert Opin. Ther. Pat. 2009, 19:237-264.
72. Holliday N.D., et al. Drug discovery opportunities and challenges at G protein coupled receptors for long chain free fatty acids. Front. Endocrinol. 2011, 2:112.
73. Negoro N., et al. Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist. ACS Med. Chem. Lett. 2010, 1:290-294.
74. Naik H., et al. Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J. Clin. Pharmacol. 2012, 52:1007-1016.
75. Houze J.B., et al. AMG 837: a potent, orally bioavailable GPR40 agonist. Bioorg. Med. Chem. Lett. 2012, 22:1267-1270.
76. Tikhonova I.G., et al. Bidirectional, iterative approach to the structural delineation of the functional "chemoprint" in GPR40 for agonist recognition. J Med Chem 2007, 50:2981-2989.
77. Sum C.S., et al. Identification of residues important for agonist recognition and activation in GPR40. J. Biol. Chem. 2007, 282:29248-29255.
78. Smith N.J., et al. The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1. J. Biol. Chem. 2009, 284:17527-17539.
79. Lin D.C-H., et al. Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Mol. Pharmacol. 2012, 82:843-859.
80. Rajagopal S., et al. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nat. Rev. Drug Discov. 2010, 9:373-386.
81. Ogawa T., et al. GPR40 gene Arg211His polymorphism may contribute to the variation of insulin secretory capacity in Japanese men. Metabolism 2005, 54:296-299.
82. Hamid Y.H., et al. Studies of relationships between variation of the human G protein-coupled receptor 40 Gene and type 2 diabetes and insulin release. Diabet. Med. 2005, 22:74-80.
83. Sum C.S., et al. Two arginine-glutamate ionic locks near the extracellular surface of FFAR1 gate receptor activation. J. Biol. Chem. 2009, 284:3529-3536.